Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: Associations with clinicopathological variables and patient survival

International Journal of Biological Markers

Volumn 24, Issue 4, 2009, Pages 245-252

  Giaginis, Constantinos ^a   Nikiteas, Nikolaos ^a   Margeli, Alexandra ^a   Tzanakis, Nikolaos ^a   Rallis, Georgios ^a   Kouraklis, Gregorios ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Colon cancer; Diagnosis; Disease stage; Prognosis; Serum; TIMP 1; TIMP 2; Tumor grade

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; QUANTITATIVE STUDY; TUMOR DIFFERENTIATION;

EID: 76649087994     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2010.2263     Document Type: Article

References (41)

1. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121-5.
2. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
3. Jiang Y, Goldberg ID, Shi YE. Complex role of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-52.
4. Alo-Aho R, Kahari VM. Colagenases in cancer. Biochimie 2005; 87: 273-86.
5. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008; 1: re6.
6. Sørensen NM, Sørensen IV, Würtz SØ, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008; 43: 774-86.
7. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006; 25: 99-113.
8. Mylona E, Magkou C, Giannopoulou I, et al. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res 2006; 8: R57.
9. Mino N, Takenaka K, Sonobe M, et al. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol 2007; 95: 250-7.
10. Hilska M, Roberts PJ, Collan YU, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121: 714-23.
11. Branca M, Ciotti M, Giorgi C, et al; HPV-PathogenISS Study Group. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. Anticancer Res 2006; 26: 1543-56.
12. Sharma R, Chattopadhyay TK, Mathur M, Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology 2004; 67: 300-9.
13. Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Daraï E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol 2006; 7: 637-45.
14. Gakiopoulou H, Nakopoulou L, Siatelis A, et al. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 2003; 9: 5573-81.
15. Sørensen NM, Schrohl AS, Jensen V, Christensen IJ, Nielsen HJ, Brünner N. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer. Scand J Gastroenterol 2008; 43: 186-91.
16. Schrohl AS, Mueller V, Christensen IJ, Pantel K, Thomssen C, Bruenner N. A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. Tumour Biol 2008; 29: 181-7.
17. Ylisirniö S, Höyhtyä M, Mäkitaro R, et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001; 7: 1633-7.
18. Wang CS, Wu TL, Tsao KC, Sun CF. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Ann Clin Lab Sci 2006; 36: 23-30.
19. Honkavuori M, Talvensaari-Mattila A, Puistola U, Turpeenniemi-Hujanen T, Santala M. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Res 2008; 28: 2715-9.
20. R uokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res 2005; 11: 3257-64.
21. Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res 2007; 27: 2753-8.
22. Vasala K, Turpeenniemi-Hujanen T. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin Biochem 2007; 40: 640-4
23. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-9.
24. Joo YE, Seo KS, Kim J, et al. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma. J Korean Med Sci 1999; 14: 417-23.
25. Schwandner O, Schlamp A, Broll R, Bruch HP. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis 2007; 22: 127-36.
26. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 6: 4292-9.
27. Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005; 48: 700-10.
28. Holten-Andersen MN, Nielsen HJ, Sørensen S, Jensen V, Brünner N, Christensen IJ. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 2006; 42: 1889-96.
29. Yukawa N, Yoshikawa T, Akaike M, et al. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology 2007; 72: 205-8.
30. Sørensen NM, Byström P, Christensen IJ, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 2007; 13: 4117-22.
31. Oberg A, Höyhtyä M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000; 20: 1085-91.
32. Ishida H, Murata N, Hayashi Y, Tada M, Hashimoto D. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg Today 2003; 33: 885-92.
33. Hanke B, Wein A, Martus P, et al. Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy. Br J Cancer 2003; 88: 1248-50.
34. Larsen MB, Stephens RW, Brünner N, et al. Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients. Scand J Immunol 2005; 61: 449-60.
35. Green FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, eds. Cancer Staging Manual. 6th ed. New York, NY: Springer Verlag, 2002.
36. Holten-Andersen MN, Christensen IJ, Nielsen HJ, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8: 156-64.
37. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 2000; 87: 1215-21.
38. Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K, Kobayashi M. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol 1996; 26: 303-9.
39. R oca F, Mauro LV, Morandi A, et al. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol 2006; 93: 151-60.
40. Nielsen HJ, Brünner N, Frederiksen C, et al; Danish-Australian Endoscopy Study Group on Colorectal Cancer Detection; Danish Colorectal Cancer Cooperative Group. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian Endoscopy Study Group on Colorectal Cancer Detection. Scand J Gastroenterol 2008; 43: 242-8.
41. Frederiksen CB, Lomholt AF, Lottenburger T, et al. Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 2008; 23: 42-7.